Bicocca Open Archive

Logo unimib boa
TETTAMANTI, SARAH
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.686
AS - Asia 2.597
EU - Europa 2.109
SA - Sud America 379
AF - Africa 80
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.863
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.500
SG - Singapore 842
IT - Italia 797
CN - Cina 502
HK - Hong Kong 342
VN - Vietnam 332
BR - Brasile 300
DE - Germania 230
RU - Federazione Russa 230
IE - Irlanda 189
CA - Canada 141
SE - Svezia 136
GB - Regno Unito 116
IN - India 111
FR - Francia 96
BD - Bangladesh 94
ID - Indonesia 67
FI - Finlandia 55
KR - Corea 48
ES - Italia 40
JP - Giappone 40
IQ - Iraq 38
PL - Polonia 38
ZA - Sudafrica 35
NL - Olanda 34
TR - Turchia 31
UA - Ucraina 31
PK - Pakistan 29
MX - Messico 25
AT - Austria 24
AR - Argentina 23
IR - Iran 20
CH - Svizzera 19
PH - Filippine 17
SA - Arabia Saudita 16
BE - Belgio 15
DK - Danimarca 13
VE - Venezuela 11
CO - Colombia 10
EC - Ecuador 10
LT - Lituania 9
IL - Israele 8
NP - Nepal 8
RO - Romania 8
TW - Taiwan 8
AU - Australia 7
EG - Egitto 7
JM - Giamaica 7
RS - Serbia 7
CL - Cile 6
KZ - Kazakistan 6
MA - Marocco 6
PE - Perù 6
UZ - Uzbekistan 6
CZ - Repubblica Ceca 5
NO - Norvegia 5
PY - Paraguay 5
TN - Tunisia 5
AE - Emirati Arabi Uniti 4
CI - Costa d'Avorio 4
DZ - Algeria 4
JO - Giordania 4
KE - Kenya 4
LB - Libano 4
MY - Malesia 4
UY - Uruguay 4
AL - Albania 3
AO - Angola 3
BO - Bolivia 3
CR - Costa Rica 3
ET - Etiopia 3
NZ - Nuova Zelanda 3
PA - Panama 3
PS - Palestinian Territory 3
SK - Slovacchia (Repubblica Slovacca) 3
AM - Armenia 2
DO - Repubblica Dominicana 2
HR - Croazia 2
MN - Mongolia 2
MU - Mauritius 2
OM - Oman 2
SC - Seychelles 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AG - Antigua e Barbuda 1
AZ - Azerbaigian 1
BB - Barbados 1
BF - Burkina Faso 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BZ - Belize 1
CG - Congo 1
CY - Cipro 1
GA - Gabon 1
GR - Grecia 1
GY - Guiana 1
HN - Honduras 1
HU - Ungheria 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MO - Macao, regione amministrativa speciale della Cina 1
Totale 8.857
Salva come PNG Salva come JPEG
Città #
Singapore 499
Ashburn 438
Ann Arbor 429
Hong Kong 319
San Jose 307
Milan 247
Chandler 186
Dublin 183
Frankfurt am Main 133
Los Angeles 125
New York 117
Fairfield 114
Ho Chi Minh City 109
Beijing 84
Hanoi 80
Wilmington 79
Dallas 78
Seattle 77
Hefei 72
Santa Clara 70
Toronto 70
Houston 68
Chicago 62
Woodbridge 62
The Dalles 58
Jakarta 51
Shanghai 49
Cambridge 47
Council Bluffs 45
Bergamo 42
Denver 40
Seoul 38
Princeton 37
São Paulo 37
Buffalo 36
Tokyo 34
Montreal 33
Munich 32
Helsinki 29
Dearborn 28
Orem 27
Johannesburg 25
Lauterbourg 25
Warsaw 24
Lissone 22
Nanjing 22
Boardman 20
Moscow 20
London 18
Poplar 17
Rome 17
Stockholm 17
Paris 16
Turin 16
Altamura 15
Atlanta 15
Brussels 15
Mumbai 15
Lahore 14
Lappeenranta 14
Vienna 14
Zurich 14
Baghdad 13
Brooklyn 13
Haiphong 13
Jacksonville 13
Lawrence 13
Manchester 13
Monza 13
Da Nang 12
Desio 12
Hyderabad 12
Nuremberg 12
Borgomanero 11
Genoa 11
Andover 10
Ankara 10
Carate Brianza 10
Carrboro 10
Cinisello Balsamo 10
Naples 10
Phoenix 10
Seregno 10
Boston 9
Chennai 9
Dhaka 9
Newark 9
Turku 9
Barnet 8
Bologna 8
Brasília 8
Fremont 8
Hải Dương 8
Jeddah 8
Kent 8
Kingston 8
Memphis 8
New Delhi 8
Pune 8
Wroclaw 8
Totale 5.428
Salva come PNG Salva come JPEG
Nome #
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities 455
Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human Studies 440
Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System 425
Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia 408
MALDI-MSI Pilot Study Highlights Glomerular Deposits of Macrophage Migration Inhibitory Factor (MIF) as a Possible Indicator of Response to Therapy in Membranous Nephropathy 399
Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia 383
CXCR4-MODIFIED CD33.CAR-CIK WITH ENHANCED BONE MARROW HOMING IN ACUTE MYELOID LEUKEMIA 360
Transposon-Based CAR T Cells in Acute Leukemias: Where are We Going? 359
Unlocking the Heterogeneity in Acute Leukaemia: Dissection of Clonal Architecture and Metabolic Properties for Clinical Interventions 310
Selective homing of CAR-CIK cells to the bone marrow niche enhances control of the Acute Myeloid Leukemia burden 295
Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use 288
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation 280
Overexpression of CXCR4 receptor on CD33.CAR-CIK cells enhances the control of the Acute Myeloid Leukemia burden 270
Generation of CIK cells co-expressing CXCR4 and CD33.CAR with improved homing and antitumor activity for AML 264
Catch me if you can: how AML and its niche escape immunotherapy 260
Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia 257
Optimized GMP-grade production of non-viral Sleeping Beauty-generated CARCIK cells for enhanced fitness and clinical scalability 255
Combining the expression of CD33.CAR and CXCR4 to augment CAR-CIKs homing to bone marrow niche and leukemic stem cell eradication in acute myeloid leukemia 251
IL3-zetakine combined with a CD33 costimulatory receptor as a Dual CAR approach for safer and selective targeting of AML 247
Overexpression of CXCR4 Enhances the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia 247
Cellule CD33.CAR-CIK ingegnerizzate per co-esprimere il recettore CXCR4 al fine di aumentare la capacità di migrazione all’interno della nicchia midollare nella leucemia mieloide acuta 246
Update on: proteome analysis in thyroid pathology - part II: overview of technical and clinical enhancement of proteomic investigation of the thyroid lesions 245
CARs are sharpening their weapons 241
Combining the Expression of CD33.CAR and CXCR4 to Increase CAR-CIK Cell Homing to Bone Marrow Niche and Leukemic Stem Cell Eradication in Acute Myeloid Leukemia 233
Carcik-CD19 Cells Expand In Vivo Toward a CD8+ Memory Phenotype and Their Persistence Is Associated with a Longer Duration of Response 232
Improving Bone Marrow Homing and Persistence of CD33.CAR-CIK Cells By Overexpression of a Gain-of-Function Variant of CXCR4 to Increase Efficacy in Acute Myeloid Leukemia 221
Engineering tandem CD33xCD146 CAR CIK (cytokine-induced killer) cells to target the acute myeloid leukemia niche 217
Ingegnerizzazione di cellule CD33.CAR-CIK con una variante gain-of-function del recettore CXCR4 per aumentarne migrazione e persistenza nella nicchia midollare 199
Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies 197
The management of haemoglobin interference for the MALDI-MSI analysis of in-vivo thyroid biopsies 187
Acute Myeloid Leukemia (AML) immunotherapy: development of TIM3-CD33 targeted Dual CAR CIK cells for eradication of LSCs in the bone marrow niche 176
Functional Activity of Cytokine-Induced Killer Cells Enhanced by CAR-CD19 Modification or by Soluble Bispecific Antibody Blinatumomab 175
Advancing CIK cell immunotherapy: highlights from the second international conference on DC-CIK and CAR-CIK approaches 36
Totale 9.058
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.804
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.804
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202141 0 0 0 0 0 0 0 0 0 0 0 41
2021/2022335 23 33 22 18 20 18 11 15 24 32 24 95
2022/2023703 91 164 69 65 16 93 19 51 49 4 58 24
2023/2024723 31 29 45 59 72 171 117 46 59 19 14 61
2024/20251.639 62 111 134 65 109 103 125 74 150 247 165 294
2025/20264.486 569 249 315 617 618 236 665 154 308 404 233 118
Totale 9.058